NMT Medical Launches Rapid Transport Septal Implant Delivery System in France

BOSTON & PARIS--(BUSINESS WIRE)--NMT Medical, Inc. (NASDAQ: NMTI) announced today at EuroPCR 2010 that it launched its RT^2™ Delivery System, a pivotal breakthrough in septal implant delivery.

“Until now, the interventional cardiologist implanting a BioSTAR® or STARFlex® had to manually attach the delivery system in the cath-lab”

The RT² Delivery System is a rapid transport enhancement that is pre-attached to NMT’s BioSTAR® and STARFlex® implants. The delivery system is designed to allow physicians to easily set the implant to conform to a patient’s individual anatomy and avoid septal distortion and unnecessary repositioning.

“Until now, the interventional cardiologist implanting a BioSTAR® or STARFlex® had to manually attach the delivery system in the cath-lab,” said NMT President and Chief Executive Officer Frank Martin. “We believe that the RT² Delivery System provides increased ease-of-use since the single operator delivery system is already attached and requires minimal repositioning. This new technology is yet another demonstration of NMT’s commitment to making our products easy for physicians to use and maintaining our leadership position in the septal heart repair space.”

The RT²Delivery System is available in France. The Company expects to launch the system in countries throughout Europe over the next several months.

About NMT Medical, Inc.

NMT Medical is an advanced medical technology company that designs, develops, manufactures and markets proprietary implant technologies that allow interventional cardiologists to treat structural heart disease through minimally invasive, catheter-based procedures. NMT is currently investigating with its CLOSURE I clinical trial, the potential connection between a common heart defect that allows a right-to-left shunt or flow of blood through a defect like a patent foramen ovale (PFO) and brain attacks such as embolic stroke, transient ischemic attacks (TIAs) and migraine headaches. A common right-to-left shunt can allow venous blood, unfiltered and unmanaged by the lungs, to enter the arterial circulation of the brain, possibly triggering a cerebral event or brain attack. More than 32,000 PFOs have been treated globally with NMT's minimally invasive, catheter-based implant technology.

Stroke is a leading cause of death in the United States and the leading cause of disability in adults. Each year, 750,000 Americans suffer a new or recurrent stroke and an additional 500,000 Americans experience a TIA.

For more information about NMT Medical, please visit www.nmtmedical.com.

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties or other factors that may cause actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Factors that might cause such a difference include, but are not limited to, those discussed under the heading “Risk Factors” included in the Management's Discussion and Analysis of Financial Condition and Results of Operations in the Company’s Annual Report on Form 10-K for the year ended December 31, 2009, Quarterly Report on Form 10-Q for the period ended March 31, 2010, and subsequent filings with the U.S. Securities and Exchange Commission.